Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S364000, C514S415000, C514S452000, C514S459000, C514S602000, C514S604000, C548S125000, C548S506000, C549S430000, C549S495000, C564S084000, C564S090000, C564S092000, C564S093000
Reexamination Certificate
active
10457641
ABSTRACT:
Compounds of Formula I,wherein R1–R8are defined herein are provided, together with pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these compounds for inhibiting beta amyloid production and for the prevention and treatment of Alzheimer's Disease and Down's syndrome are described.
REFERENCES:
patent: 4070176 (1978-01-01), Oshio et al.
patent: 4113463 (1978-09-01), Oshio et al.
patent: 5571821 (1996-11-01), Chan et al.
patent: 5591761 (1997-01-01), Chan et al.
patent: 5594021 (1997-01-01), Chan et al.
patent: 5852007 (1998-12-01), Chatterjee
patent: 5962490 (1999-10-01), Chan et al.
patent: 5977117 (1999-11-01), Chan et al.
patent: 6030991 (2000-02-01), Chan et al.
patent: 6248775 (2001-06-01), Vazquez et al.
patent: 6265428 (2001-07-01), Chan et al.
patent: 6331637 (2001-12-01), Chan et al.
patent: 6342610 (2002-01-01), Chan et al.
patent: 6376523 (2002-04-01), Chan et al.
patent: 6541498 (2003-04-01), Chan et al.
patent: 6610734 (2003-08-01), Kreft et al.
patent: 2003/0013892 (2003-01-01), Resnick et al.
patent: 2004/0097572 (2004-05-01), Smith et al.
patent: 2005/0038099 (2005-02-01), Tung et al.
patent: 2005/0245573 (2005-11-01), Neitzel et al.
patent: 2006/0063799 (2006-03-01), Gilligan
patent: 838 004 (1952-05-01), None
patent: 25 44 859 (1976-04-01), None
patent: 0 081 425 (1983-06-01), None
patent: 0 611 756 (1994-08-01), None
patent: 1 088 821 (2001-04-01), None
patent: WO-00/50391 (2000-08-01), None
patent: WO-01/23379 (2001-04-01), None
patent: 2005/090296 (2005-09-01), None
Ito et al., Chemical Abstracts, 120:270114, 1994.
Li et al., “The Amyloid Precursor Protein of Alzheimer Disease in Human Brain and Blood”, J. Leukocyte Biol., 66: 567 (Oct. 1999).
Näslund et al., “Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline”, J. Am. Med. Assoc., 283(12): 1571 (Mar. 22/29, 2000).
Small et al., “Alzheimer's Disease and the Amyloid β Protein: What Is the Role of Amyloid?”, J. Neurochem., 73(2):443 (Aug. 1999).
Dodart et al., “The β-Amyloid Precursor Protein and its Derivatives: From Biology to Learning and Memory Processes”, Rev. in the Neurosci., 11(2-3):75-93 (2000).
Wolfe, “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”, J. Med. Chem., 44(13): 2039 (Jun. 21, 2001).
Goate, “Monogenetic Determinants of Alzheimer's Disease:APPMutations”, Cell. Mol. Life Sci., 54:897-901 (Sep. 1998).
Sabbagh et al., “β-Amyloid and Treatment Opportunities for Alzheimer's Disease”, Alzheimer's Dis. Rev., 3:1-19 (1997).
Skovronsky et al., “β-Secretase Revealed: Starting Gate for Race to Novel Therapies for Alzheimer's Disease”, Trends Pharmacol. Sci., 21:161-163 (2000).
Sinha et al., “Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain”, Nature, 402:537 (Dec. 2, 1999).
Ghosh et al., “Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)”, J. Am. Chem. Soc., 122:3522-3523 (2000).
Esler et al., “Transition-State Analogue Inhibitors of γ-Secretase Bind Directly to Presenilin-1”, Nature Cell Biol., 2:428 (Jul. 2000).
Li et al., “Photoactivated γ-Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1”, Nature, 405: 689 (Jun. 8, 2000).
Olson et al., “Chapter 4. Secretase Inhibitors as Therapeutics for Alzheimer's Disease”, Ann. Reports in Med. Chem., 35:31 (2000).
Dovey et al., “Functional Gamma-Secretase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain”, J. Neurochem., 76:173-181 (Jan. 2001).
Augelli-Szafran et al., “Chapter 3. β-Amyloid as a Target for Alzheimer's Disease Therapy”, Ann. Reports in Med. Chem., 34:21 (1999).
Moore et al., “Inhibition of β-Amyloid Formation as a Therapeutic Strategy”, Exp. Opin. Ther. Patents, 9(2):135-146 (1999).
Varghese et al., “Chapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis”, Ann. Reports Med. Chem., 32:11 (1997).
Larner et al., “Alzheimer's Disease: Towards Therapeutic Manipulation of the Amyloid Precursor Protein and Amyloid β-Peptides”, Exp. Opin. Ther. Patents, 7(10): 1115-1127 (1997).
Rishton et al., “Fenchylamine Sulfonamide Inhibitors of Amyloid βPeptide Production by the γ-Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease”, J. Med. Chem., 43:2297 (Jun. 15, 2000).
Hertler et al., “Free-Radical Chain Isomerization of N-Vinylsulfonamides”, J. Org. Chem., 39(22):3219 (1974).
Cho et al., “Catalytic Enantioselective Reactions. Part 12. Enantioselective Addition of Diethylzinc to Aldehydes Catalyzed by Zinc Complexes Modified with Chiral β-Sulfonamidoalcohols”, Syn. Commun., 29(3):521-531 (1999).
Ito et al., “Enantioselective Addition of Diethylzinc to Aldehydes in the Presence of Chiral Titanium Reagent Modified with N-Sulfonylated Amino Alcohol”, Synlett., 7:573-574 (1992).
Itsuno et al., “Enantioselective Synthesis of Optically Active Homoallylamines by Nucleophilic Addition of Chirally Modified Allylboranes to N-silylamines”, J. Chem. Soc. Perkin Trans. 1:2011-2016 (1999).
Defauw et al., “Synthesis and Protein Kinase C Inhibitory Activities of Acyclic Balanol Analogs that are Highly Selective for Protein Kinase C Over Protein Kinase A”, J. Med. Chem., 39:5215-5227 (Dec. 1996).
Findeis et al., “Modified Peptide Inhibitors of Amyloid-Beta-Polymerization”, Am. Chem. Soc. Biochem. 38(21): 6791-6800 (May 25, 1999).
Abstract of Japanese Patent No. JP-5-148233 (Jun., 15 1993).
Abstract of Japanese Patent No. JP-11-343279 (Dec. 14, 1999).
Abstract of European Patent No. 081 425 (Jun., 15 1983).
Rishton et al., “Computational Approaches to the Prediction of Blood-Brain Barrier Permeability: A Comparative Analysis of Central Nervous System Drugs Versus Secretase Inhibitors for Alzheimer's Disease”, Curr. Opinion. Drug Discovery & Development, 9(3): 303 (May, 2006).
Casebier David Scott
Cole Derek Cecil
Kreft Anthony Frank
Kubrak Dennis Martin
Kutterer Kristina Martha
ArQule, Inc.
Barrett Rebecca R.
Howson & Howson LLP
Powers Fiona T.
Wyeth
LandOfFree
Substituted phenylsulfonamide inhibitors of beta amyloid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted phenylsulfonamide inhibitors of beta amyloid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenylsulfonamide inhibitors of beta amyloid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3749157